Daratumumab Alternatives Compared
Daratumumab | Darzalex | Abecma |
|
---|
Daratumumab | Darzalex (daratumumab) | Abecma (idecabtagene vicleucel) |
|
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Multiple Myeloma. daratumumab may also be used for purposes not listed in this medication guide. |
Prescription only
Darzalex is a CD38 monoclonal antibody that may be used to treat Multiple Myeloma, usually in combination with other treatments. It is given by infusion and upper respiratory tract infections... View more |
Prescription only
Prescribed for Multiple Myeloma. Abecma may also be used for purposes not listed in this medication guide. |
Related suggestions Multiple Myeloma
|
|||||||||||||||
More about Daratumumab | More about Darzalex (daratumumab) | More about Abecma (idecabtagene vicleucel) | ||||||||||||||||
Ratings & Reviews | ||||||||||||||||||
Daratumumab has an average rating of 8.1 out of 10 from a total of 16 ratings on Drugs.com. 75% of reviewers reported a positive effect, while 13% reported a negative effect. |
Darzalex has an average rating of 7.3 out of 10 from a total of 4 ratings on Drugs.com. 75% of reviewers reported a positive effect, while 25% reported a negative effect. |
Be the first to share your experience with this drug. |
||||||||||||||||
Drug Class | ||||||||||||||||||
Side Effects | ||||||||||||||||||
See also: daratumumab side effects in more detail. |
See also: Darzalex side effects in more detail. |
See also: Abecma side effects in more detail. |
||||||||||||||||
Generic Availability | ||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Darzalex prices |
View all Abecma prices |
||||||||||||||||
Dosage Form(s) Available | ||||||||||||||||||
N/A |
|
|
||||||||||||||||
Brand Names | ||||||||||||||||||
Darzalex |
N/A |
N/A |
||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||
432 hours |
432 hours |
N/A |
||||||||||||||||
CSA Schedule ** View glossary of terms | ||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
Pregnancy Category | ||||||||||||||||||
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
Drug Interactions | ||||||||||||||||||
A total of 168 drugs are known to interact with daratumumab:
|
A total of 168 drugs are known to interact with Darzalex:
|
A total of 199 drugs are known to interact with Abecma:
|
||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
Disease Interactions | ||||||||||||||||||
First Approval Date | ||||||||||||||||||
N/A |
November 16, 2015 |
N/A |
||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||
More Information | ||||||||||||||||||
Patient resources | ||||||||||||||||||
Professional Resources | ||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.